NCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
Clinical Trials
21 trialsNCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT06324357 2026-04-15
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT07494448 2026-03-27
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting
NCT06282575 2026-03-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07102381 2026-03-12
EmpowHER 208
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT06435429 2026-02-10
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07176312 2026-02-04
ZANGEA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05035836 2025-12-22
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07296705 2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2 Recruiting
NCT07192068 2025-12-19
AcSé HER2
UNICANCER
Phase 2 Recruiting
NCT07243938 2025-11-24
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05027139 2025-10-16
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04224272 2025-08-01
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04578444 2025-05-25
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Jazz Pharmaceuticals
No longer available
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting